Recursion is building an industrialized engine for medicine. It operates among biotech stocks, selling access to its proprietary platform and pursuing joint development with major partners like Roche ...

When looking at the stock market right now, the increasingly obvious question is to paraphrase that catchy 1940s tune: “Is you is, or is you ain’t, in a bubble?” ...

Add Futurism (opens in a new tab) More information Adding us as a Preferred Source in Google by using this link indicates that you would like to see more of our content in Google News results. Some of ...

A decision tree regression system incorporates a set of if-then rules to predict a single numeric value. Decision tree regression is rarely used by itself because it overfits the training data, and so ...

Claude Code generates computer code when people type prompts, so those with no coding experience can create their own programs and apps. By Natallie Rocha Reporting from San Francisco Claude Code, an ...

Here's a question with trillion-dollar consequences for the economy. Are we in an AI bubble or not? Planet Money's Jeff Guo runs us through some of the signs economists are looking for to get an ...

Recursion Pharmaceuticals (RXRX) added ~11% in the morning trading on Wednesday after J.P. Morgan upgraded the AI-driven biotech to Overweight from Neutral, citing a blockbuster sales potential for ...

Three Harvard faculty said they think fears that an artificial intelligence bubble will burst — leading stock prices to collapse in the wake of soaring investments into AI companies — are overblown ...

You're currently following this author! Want to unfollow? Unsubscribe via the link in your email. Michael Burry fired off a warning about the AI boom in a "Lord of the Rings" wrapper on Sunday, and ...

After a challenging 12 years trying to use AI to create new medicines, cofounder Chris Gibson stepped down as CEO last week. Can R&D chief and new CEO Najat Khan turn it around? In 2014, Recursion ...